Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open Label Study to Evaluate the Predictability of Early Response to Certolizumab Pegol (in Combination With Methotrexate) as Confirmed at Week 52 in Subjects With Moderate-severe Rheumatoid Arthritis (RA)

NCT01443364 is registered in ClinicalTrials.gov with UCB Italy s.p.a. as lead sponsor.

NCT NCT01443364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01443364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open Label Study to Evaluate the Predictability of Early Response to Certolizumab Pegol (in Combination With Methotrexate) as Confirmed at Week 52 in Subjects With Moderate-severe Rheumatoid Arthritis (RA)
Lead sponsor
UCB Italy s.p.a.
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2011
Completion date
May 31, 2015
Enrollment
132 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis